Xeris (XERS) Q1 2026: Recorlev Surges 95%, Fueling Raised Guidance and Pipeline Ambitions

2026-05-07 | By EarningsIQ Research

Record Recorlev growth and commercial expansion drove Xeris to raise its 2026 revenue outlook, despite GVOKE headwinds. The company’s pipeline progress and disciplined capital allocation signal a pivot to sustained profitability and future portfolio leverage. Investors should watch for second-half inflections as new sales capacity and pipeline milestones converge.

Summary

• Recorlev Outperformance Resets Growth Baseline: Commercial momentum in Recorlev nearly doubled revenue, offsetting GVOKE softness.
• Pipeline and Infrastructure Investment Accelerates: Xeris is scaling for XP8121 Phase 3 and expanding sales force to capture future upside.
• Second-Half Leverage in Focus: Expanded commercial footprint and product mix shifts set up for incremental margin and revenue gains later in 2026.

Business Overview

Xeris Biopharma is a specialty pharmaceutical company focused on endocrinology and rare diseases. The company generates revenue through three main products: Recorlev, a therapy for hypercortisolemia and Cushing’s syndrome; GVOKE, a ready-to-use glucagon rescue; and Cabeus, a treatment for primary periodic paralysis in an ultra-rare patient population. Xeris also advances a pipeline leveraging its proprietary Xerosol formulation technology, aiming to address unmet needs in hypothyroidism with XP8121.

Performance Analysis

Q1 2026 saw Xeris deliver robust revenue growth, powered by a 95% surge in Recorlev, which contributed $50 million and now represents the majority of the portfolio’s growth engine. Cabeus delivered its second consecutive quarter of year-over-year growth, while GVOKE stalled due to Medicare reset impacts and higher patient out-of-pocket costs. The company’s gross margin improved to 87%, reflecting favorable product mix, especially the higher-margin profile of Recorlev.

Operating leverage was evident as adjusted EBITDA improved by $10.7 million year-over-year, and net income swung to a positive $2.2 million. SG&A and R&D expenses rose as Xeris invested in a near-doubling of its commercial team and advanced XP8121 towards Phase 3, but these increases were aligned with the company’s growth trajectory. The company raised the low end of its full-year revenue guidance, citing strong portfolio performance and confidence in sustained demand trends.

• Product Mix Shift Drives Margin Expansion: Higher Recorlev sales and stable Cabeus volumes improved gross margin by 2 percentage points.
• GVOKE Faces Medicare Headwinds: Flat revenue and prescription softness highlight payer and coverage risk, but recovery is expected as the year progresses.
• Disciplined Cost Scaling: Incremental SG&A and R&D spend are tightly linked to commercial expansion and pipeline milestones, maintaining profitability focus.

Xeris’ ability to absorb GVOKE’s weak quarter while delivering both top-line and bottom-line growth signals a maturing, diversified model with leverage potential as new growth vectors come online.

Executive Commentary

Strategic Positioning

1. Recorlev as the Core Growth Engine

Recorlev’s near-doubling in revenue and continued patient uptake position it as Xeris’ central growth lever. The commercial expansion, which increased the sales force to 80 reps and expanded the target physician base by 6,000, is expected to yield incremental volume and market penetration, particularly in the second half of 2026. The majority of Recorlev patients are new to therapy, indicating ongoing addressable market expansion.

2. Pipeline Progress and Platform Leverage

XP8121, a hypothyroidism candidate leveraging Xerosol technology, is on track for Phase 3 initiation by year-end. Xeris is deliberately sequencing device, formulation, and go-to-market readiness before trial start, aiming to maximize commercial impact post-approval. The pipeline strategy is designed to amplify the value of existing commercial infrastructure and technology platforms.

3. Commercial and Patient Support Infrastructure Build-Out

The company’s investment in sales and patient services is designed to capture more referrals and new patient starts, particularly as payer resets and seasonality abate. Expansion in reimbursement and pharmacy support is expected to further reduce access friction and improve conversion rates across the portfolio.

4. Disciplined Capital Allocation and Optionality

Management emphasized reinvestment in growth as the primary capital allocation priority, with optionality for external innovation or pipeline expansion if it aligns with Xeris’ commercial and R&D strengths. The improved balance sheet and positive EBITDA profile provide flexibility for future inorganic or organic growth moves.

Key Considerations

Xeris’ Q1 performance reflects a company executing on multiple fronts, balancing rapid revenue growth with foundational investments in both commercial and pipeline assets. The interplay between payer dynamics, product mix, and infrastructure expansion will define near-term results, while pipeline execution and capital discipline set the stage for longer-term upside.

Key Considerations:

• Recorlev’s Rising Share: Sustained momentum in Recorlev is critical, as it increasingly anchors both revenue and margin trajectory.
• GVOKE Recovery Pace: The speed and magnitude of GVOKE’s prescription recovery post-Medicare reset will influence full-year revenue mix and growth.
• Commercial Expansion Lag: The impact of the expanded sales force is expected to be back-half weighted, highlighting execution risk and opportunity.
• Pipeline Timing and Readiness: XP8121’s go-to-market preparation is essential for a smooth Phase 3 start and future commercial leverage.
• Capital Allocation Flexibility: Management’s willingness to pursue external or internal pipeline opportunities could accelerate portfolio diversification if disciplined.

Risks

Payer and reimbursement volatility remains a material risk, as evidenced by GVOKE’s Q1 performance drag from Medicare resets and patient out-of-pocket increases. Pipeline execution delays or commercial missteps in scaling new sales capacity could undermine top-line momentum. Competitive dynamics, especially in ready-to-use glucagon, and the need for continued patient and provider education, present ongoing challenges. Investors should also monitor for any overextension in SG&A or R&D spend relative to realized growth.

Forward Outlook

For Q2 2026, Xeris guided to:

• Continued revenue strength, led by Recorlev and incremental contributions from commercial expansion.
• Modest GVOKE recovery as prescription volumes rebound post-Q1 headwinds.

For full-year 2026, management raised guidance:

• Total revenue of $380 to $390 million, representing over 30% growth.

Management highlighted several factors that shape the outlook:

• Second-half weighted benefit from expanded Recorlev sales force and patient support infrastructure.
• XP8121 Phase 3 initiation and continued margin improvement from product mix.

Takeaways

Xeris’ Q1 validated its commercial model and pipeline approach, while demonstrating operating leverage and capital discipline.

• Recorlev’s Breakout Quarter: Nearly doubled revenue, confirming product-market fit and providing a strong foundation for future growth.
• Execution on Multiple Levers: Commercial, pipeline, and financial management all contributed to outperformance and improved outlook.
• Second-Half Inflection Watch: Investors should monitor for sales force productivity gains and XP8121 milestones as the year progresses.

Conclusion

Xeris entered 2026 with strong commercial momentum and a clear focus on scaling both its core products and pipeline. With Recorlev now firmly established as the growth engine, the company’s disciplined investments position it for incremental upside as new capacity and pipeline milestones come online.

Industry Read-Through

Xeris’ results reinforce the value of focused commercial expansion and platform leverage in specialty pharma, especially for products addressing high unmet need and rare disease markets. The impact of payer resets and Medicare policy changes on prescription fill rates provides a cautionary signal for peers with similar channel exposure, highlighting the need for robust patient support and pricing agility. Pipeline programs that utilize existing commercial and technological infrastructure, as seen with XP8121, may offer an efficient path to incremental growth for other specialty and rare disease firms. The company’s approach to capital allocation and readiness to consider external innovation also signals a broader industry trend toward portfolio diversification and disciplined growth investment.

XERS Healthcare Pharmaceuticals Specialty Pharma Endocrinology Pipeline Commercial Expansion Revenue Growth